博奥生物品牌怎么样 申请店铺

我要投票 博奥生物在基因检测行业中的票数:356 更新时间:2025-08-01
博奥生物是哪个国家的品牌?「博奥生物」是 博奥生物集团有限公司 旗下著名品牌。该品牌发源于北京市,由创始人程总在2000年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力博奥生物品牌出海!将品牌入驻外推网,定制博奥生物品牌推广信息,可以显著提高博奥生物产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

博奥生物怎么样

成立于2000年,清华控股旗下,生命科学研究和健康产业的企业,打造集健康产品/健康管理和医疗康复于一体的大健康产业版块。

博奥生物集团有限公司于2000年9月30日在国务院、发改委、科技部、教育部、卫生部和北京市领导大力支持下,以清华大学为依托、联合华中科技大学、中国医学科学院、军事医学科学院注册成立,是生命科学研究和健康产业的国有创新型高科技企业。公司总部位于北京,现有员工2000多人,研发、生产、运营和服务基地超过10万平方米。

公司以生物芯片为核心技术平台,拥有研发、生产、销售以及全国第三方独立医学检验所服务为一体的大医学完整产业链,并响应国家关于“预防为主”的健康方针,将现代医学与中国传统医学紧密结合,打造出集健康产品、健康管理和医疗康复于一体的大健康产业版块。迄今,博奥生物在国内已经形成了北京、上海、重庆、成都等大型产业化基地,并形成了以北京博奥晶典生物技术有限公司为核心的产业化平台。

成立18年来,博奥生物依托清华大学和生物芯片北京国家工程研究中心雄厚的研发实力,已成功开发出生物芯片及相关试剂耗材、仪器设备、软件数据库、生命科学服务、临床检验服务、健康管理等系列数十项具有自主知识产权的产品和服务。公司先后获得德国TÜV莱茵公司颁发的ISO9001、ISO13485、ISO14000、ISO18000、ISO27000质量管理体系认证证书、美国组织相容性及遗传学协会(ASHI)认证证书和中国合格评定国家认可委员会实验室认证证书,其产品获得CFDA、CE 、GS、CB等国内外各类认证证书100余项。至今,博奥生物已在全球获得专利授权300余项,专利转化率较高。

因其优良的研发、生产、营销和服务团队,以及生物芯片技术平台和高标准的质保体系,博奥生物除与国内近百家三甲医院、高校、公安和司法机构建立了战略合作,还与罗氏应用科学、罗氏诊断、昂飞、热电等国际生命科学和医学诊断领域的公司建立了伙伴关系,产品及服务出口北美、欧洲、亚洲等三十多个国家和地区。其中,诊断用生物芯片及相关仪器产品已进入英国、德国、瑞典、意大利、西班牙、奥地利、瑞士、葡萄牙、芬兰、丹麦、日本、新加坡等国家的数百家医院。

Founded in 2000, Tsinghua holdings, a life science research and health industry enterprise, has created a large health industry section integrating health products / health management and medical rehabilitation. On September 30, 2000, with the support of the State Council, the national development and Reform Commission, the Ministry of science and technology, the Ministry of education, the Ministry of health and the leaders of Beijing Municipality, Bo'ao biological Group Co., Ltd. was established on the basis of Tsinghua University and registered with Huazhong University of science and technology, the Chinese Academy of Medical Sciences and the Academy of Military Medical Sciences. It is a state-owned innovative high-tech enterprise in life science research and health industry. The company is headquartered in Beijing, with more than 2000 employees and over 100000 square meters of R & D, production, operation and service bases. With biochip as the core technology platform, the company has a complete industrial chain of large-scale medicine integrating R & D, production, sales and the services of the national third-party independent medical laboratory. In response to the national health policy of "prevention first", the company closely combines modern medicine with traditional Chinese medicine to create a large-scale health industry integrating health products, health management and medical rehabilitation Industry forum. So far, Boao biology has formed large-scale industrialization bases in China, such as Beijing, Shanghai, Chongqing, Chengdu, and formed an industrialization platform with Beijing Boao Jingdian Biotechnology Co., Ltd. as the core. Since its establishment 18 years ago, relying on the strong R & D strength of Tsinghua University and biochip Beijing National Engineering Research Center, BOCOG bio has successfully developed dozens of products and services with independent intellectual property rights, including biochip and related reagent consumables, instruments and equipment, software database, life science services, clinical testing services, health management, etc. The company has successively obtained ISO9001, ISO13485, ISO14000, ISO18000, ISO27000 quality management system certification issued by Germany t Ü V Rhine company, Ashi certification and laboratory certification issued by China National Accreditation for conformity assessment. Its products have obtained more than 100 kinds of certification certificates at home and abroad, such as CFDA, CE, GS, CB, etc. So far, Bo'ao biology has obtained more than 300 patent authorizations in the world, with a high patent conversion rate. Due to its excellent R & D, production, marketing and service team, as well as the biochip technology platform and high standard quality assurance system, Boao biology has established strategic cooperation with nearly 100 top three hospitals, universities, public security and judicial institutions in China, as well as partnerships with companies in international life science and medical diagnosis fields such as Roche Applied Science, Roche diagnosis, onfe, thermoelectricity, etc Products and services are exported to more than 30 countries and regions in North America, Europe and Asia. Among them, diagnostic biochip and related instrument products have entered hundreds of hospitals in Britain, Germany, Sweden, Italy, Spain, Austria, Switzerland, Portugal, Finland, Denmark, Japan, Singapore and other countries.

本文链接: https://brand.waitui.com/126365a18.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

鼎通科技:初步确定的本次询价转让价格为76.72元/股

36氪获悉,鼎通科技公告,根据2025年8月1日询价申购情况,初步确定的本次询价转让价格为76.72元/股。出让方与组织券商协商一致决定启动追加认购程序,追加认购截止时间不晚于2025年8月14日。

2小时前

倍加洁:股价异常波动,控股股东一致行动人减持股份

36氪获悉,倍加洁公告,公司股票价格于2025年7月31日和8月1日连续两个交易日内日收盘价格涨幅偏离值累计超过20%,属于股票交易异常波动情形。经自查及向控股股东、实际控制人书面发函查证,公司主营业务未发生变化,经营情况正常,不存在应披露而未披露的重大事项。公司存在控股股东、实际控制人的一致行动人减持股份计划,其中,小倍一号通过大宗交易方式减持公司股份102.5万股,小倍二号减持公司股份57.5万股。

2小时前

三安光电:拟联合境外投资人以2.39亿美元收购LumiledsHoldingB.V.100%股权

36氪获悉,三安光电公告,公司拟联合境外投资人Inari以现金2.39亿美元收购LumiledsHoldingB.V.100%股权。为确保交易顺利实施,公司与Inari拟通过各自子公司按照74.5%、25.5%的出资比例共同出资2.80亿美元在香港设立合资公司。本次交易完成后,公司将间接持有标的公司74.5%股权,并将其纳入合并报表范围。

2小时前

联创光电:拟1亿元回购子公司联创显示33.0229%股权

36氪获悉,联创光电公告,公司拟以自有或自筹资金1亿元偿还临空产业投资公司借款暨回购其持有的公司控股子公司联创显示33.0229%股权。交易完成后,联创显示将在工商登记部门办理股权过户并恢复登记为公司全资子公司。该交易不构成关联交易,不构成重大资产重组,且无需提交股东大会审议。

2小时前

格力电器回应网传文章:公司及高管不存在与“张某利”有不正当往来

36氪获悉,格力电器发布声明称,经内部核查,格力电器及其高管不存在与不实文章中提及的“张某利”有不正当往来。发帖人在未向格力电器核实的前提下,擅自指陈格力“高管内外勾结骗取侨商钱财”纯属造谣诽谤。

2小时前

本页详细列出关于博奥生物的品牌信息,含品牌所属公司介绍,博奥生物所处行业的品牌地位及优势。
咨询